AAAAAA

   
Results: 1-8 |
Results: 8
Clinical improvement in osteoarthritis - Reply
Authors: Ehrich, E Davies, G Watson, D Bolognese, J Seidenberg, B Bellamy, N
Citation: E. Ehrich et al., Clinical improvement in osteoarthritis - Reply, J RHEUMATOL, 28(8), 2001, pp. 1932-1932
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
Authors: Cannon, GW Caldwell, JR Holt, P McLean, B Seidenberg, B Bolognese, J Ehrich, E Mukhopadhyay, S Daniels, B
Citation: Gw. Cannon et al., Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, ARTH RHEUM, 43(5), 2000, pp. 978-987
A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis
Authors: Day, R Morrison, B Luza, A Castaneda, O Strusberg, A Nahir, M Helgetveit, KB Kress, B Daniels, B Bolognese, J Krupa, D Seidenberg, B Ehrich, E
Citation: R. Day et al., A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis, ARCH IN MED, 160(12), 2000, pp. 1781-1787
What are minimal important changes for asthma measures in a clinical trial?
Authors: Santanello, NC Zhang, J Seidenberg, B Reiss, TF Barber, BL
Citation: Nc. Santanello et al., What are minimal important changes for asthma measures in a clinical trial?, EUR RESP J, 14(1), 1999, pp. 23-27
Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
Authors: Ehrich, EW Schnitzer, TJ McIlwain, H Levy, R Wolfe, F Weisman, M Zeng, Q Morrison, B Bolognese, J Seidenberg, B Gertz, BJ
Citation: Ew. Ehrich et al., Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib, J RHEUMATOL, 26(11), 1999, pp. 2438-2447
Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib inpost-dental surgery pain: A randomized, controlled trial
Authors: Morrison, BW Christensen, S Yuan, WY Brown, J Amlani, S Seidenberg, B
Citation: Bw. Morrison et al., Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib inpost-dental surgery pain: A randomized, controlled trial, CLIN THER, 21(6), 1999, pp. 943-953
The safety profile, tolerability, and effective dose range of rofecoxib inthe treatment of rheumatoid arthritis
Authors: Schnitzer, TJ Truitt, K Fleischmann, R Dalgin, P Block, J Zeng, Q Bolognese, J Seidenberg, B Ehrich, EW
Citation: Tj. Schnitzer et al., The safety profile, tolerability, and effective dose range of rofecoxib inthe treatment of rheumatoid arthritis, CLIN THER, 21(10), 1999, pp. 1688-1702
Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea:A randomized controlled trial
Authors: Morrison, BW Daniels, SE Kotey, P Cantu, N Seidenberg, B
Citation: Bw. Morrison et al., Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea:A randomized controlled trial, OBSTET GYN, 94(4), 1999, pp. 504-508
Risultati: 1-8 |